Table 1.
Baseline Characteristics
| COPD (N= 3532) | ACO (N= 1276) | |
|---|---|---|
| Age, median [IQR] | 66.0 [59–74] | 60.0 [53–69] |
| Gender (% male (n)) | 57.2% (n=2020) | 49.8% (n=636) |
| BMI, median [IQR] | 26.0 [23–29] | 27.0 [24–30] |
| Age at which lung complaints starteda, median [IQR] | 57 [45–66] | 40 [12–55] |
| Age < 5 years, %(n) | 18.6% (n=657) | 19.9% (n=254) |
| Age 5–40 years, %(n) | 10.3% (n=364) | 33.5% (n=428) |
| Age ≥ 40 years | 71.1% (n=2511) | 46.6% (n=594) |
| GOLD categoryb, %(n) | ||
| A | 30.3% (n=1067) | 26.4% (n=335) |
| B | 50.7% (n=1792) | 51.3% (n=651) |
| C | 4.9% (n=171) | 5.4% (n=68) |
| D | 14.0% (n=495) | 16.9% (n=214) |
| Data available | 99.8% (n=3525) | 99.4% (n=1268) |
| Lung function, mean ± sd | ||
| FEV1 (L)c | 1.96 ± 0.71 | 2.17 ± 0.69 |
| FVC (L)c | 3.51 ± 1.02 | 3.66 ± 1.03 |
| FEV1/FVC ratioc | 55.87 ± 11.35 | 59.54 ± 9.88 |
| FEV1% predictedc | 66.22 ± 17.40 | 70.13 ± 15.19 |
| Data available, %(n) | 99.6% (n=3518) | 99.5% (n=1270) |
| Respiratory medicationd, %(n) | ||
| ICS containing treatment | 36.5% (n=1289) | 49.6% (n=636) |
| LAMA only (no ICS treatment) | 10.8% (n=383) | 1.6% (n=20) |
| LABA only (no ICS treatment) | 1.4% (n=49) | 4.9% (n=63) |
| LABA/LAMA (no ICS treatment) | 0.5% (n=18) | 0.6% (n=8) |
| Self-reported exacerbations, %(n) | ||
| None in the last 12 months | 57.1% (n=2015) | 52.4% (n=667) |
| At least one in the last 12 months | 42.9% (n=1511) | 47.6% (n=607) |
| At least two in the last 12 months | 18.9% (n=666) | 22.1% (n=282) |
| Data available | 99.8% (n=3526) | 99.8% (n=1274) |
| Smoking status, %(n) | ||
| Yes, currently smoking | 48.5% (n=1710) | 45.9% (n=585) |
| Yes, but quit ≥12 months ago | 47.8% (n=1686) | 46.2% (n=589) |
| Never smoked | 3.6% (n=128) | 7.9% (n=101) |
| Data available | 99.8% (n=3524) | 99.9% (n=1275) |
| Triggers causing symptoms, %(n) | ||
| Atopy | 16.4% (n=581) | 40.5% (n= 517) |
| Hyperreactivity | 35.5% (n=1255) | 59.0% (n= 753) |
| No triggers | 37.5% (n=1323) | 19.7% (n=252) |
| Specific IgE, %(n) | ||
| Positive screening aero allergense | 18.9% (n=94) | 28.4% (n=75) |
| Data available | 14.2% (n=498) | 20.7% (n=264) |
Notes: The percentage of data available was not provided if the percentage data available was 100%; abased on the following question “At what age did you experience lung complaints for the first time (coughing, wheezing, breathlessness)”; bbased on GOLD 2019 – CCQ; cpost-bronchodilator; dshort acting bronchodilator use is not taken into account; ePhadiaTop.
Abbreviations: COPD, chronic obstructive pulmonary disease; ACO, asthma COPD overlap; IQR, interquartile range; BMI, body mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids; LAMA, long-acting muscarinic antagonist; LABA, long-acting beta 2 agonist; IgE, immunoglobulin.